Vancomycin Trough 농도에 따른 효과 및 부작용 발생 평가
Evaluation of Efficacy and Safety Depending on the Vancomycin Trough Level
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : A recently published review on the therapeutic monitoring of the vancomycin has recommended maintaining the vancomycin trough concentration at 15-20 mg/L for severe infections caused by methicillin-resistant Staphylococcus aureus. Additionally, in Seoul St. Mary’s Hospital, the vancomycin trough concentrations above 15 mg/L are increasingly recommended for therapeutic outcome. The purpose of the study was to analyze the efficacy and safety according to the vancomycin trough concentration and to apply the trough concentration in clinical trials. Methods : A retrospective analysis was conducted among patients age 18 and older detected Gram-positive cocci at Seoul St. Mary’s Hospital and received vancomycin for three days or more October 2018-May 2019. The patients were stratified by the mean vancomycin trough concentration [T1 (<15 mg/L), T2 (≥15 mg/L)]. To evaluate the efficacy, we assessed the rate of the two consecutive growth-negative blood cultures and the mean of the c-reactive protein (CRP) change. The safety was evaluated through the percentage of the serum creatinine (SCr) and blood urea nitrogen (BUN) levels exceeding normal range after administration. Results : Of the 89 patients, 72 patients were in T1. The mean trough concentration of the vancomycin was 9.0±3.0 mg/L in T1 and 19.5±7.2 mg/L in the T2 (p<0.001). The T2 showed significantly higher rates of the two consecutive growth-negative blood cultures which were 58.8% of T2 and 26.4% in the T1 (p=0.014). The CRP change was not significantly higher in the T2 (p=0.577). The proportion of the SCr and BUN beyond the normal range after the vancomycin administration was not statistically significant different (p=0.251, p=0.154). Conclusion : The patients with the mean trough concentration of the vancomycin higher than 15 mg/L had significantly higher rates of the two consecutive growth-negative blood cultures, and there was no significant difference in the incidence of renal toxicity. Thus, increasing the vancomycin trough concentration to 15 mg/L or higher could enhance the therapeutic effect without significant increase in the nephrotoxicity.
Abstract
Background : A recently published review on the therapeutic monitoring of the vancomycin has recommended maintaining the vancomycin trough concentration at 15-20 mg/L for severe infections caused by methicillin-resistant Staphylococcus aureus. Additionally, in Seoul St. Mary’s Hospital, the vancomycin trough concentrations above 15 mg/L are increasingly recommended for therapeutic outcome. The purpose of the study was to analyze the efficacy and safety according to the vancomycin trough concentration and to apply the trough concentration in clinical trials. Methods : A retrospective analysis was conducted among patients age 18 and older detected Gram-positive cocci at Seoul St. Mary’s Hospital and received vancomycin for three days or more October 2018-May 2019. The patients were stratified by the mean vancomycin trough concentration [T1 (<15 mg/L), T2 (≥15 mg/L)]. To evaluate the efficacy, we assessed the rate of the two consecutive growth-negative blood cultures and the mean of the c-reactive protein (CRP) change. The safety was evaluated through the percentage of the serum creatinine (SCr) and blood urea nitrogen (BUN) levels exceeding normal range after administration. Results : Of the 89 patients, 72 patients were in T1. The mean trough concentration of the vancomycin was 9.0±3.0 mg/L in T1 and 19.5±7.2 mg/L in the T2 (p<0.001). The T2 showed significantly higher rates of the two consecutive growth-negative blood cultures which were 58.8% of T2 and 26.4% in the T1 (p=0.014). The CRP change was not significantly higher in the T2 (p=0.577). The proportion of the SCr and BUN beyond the normal range after the vancomycin administration was not statistically significant different (p=0.251, p=0.154). Conclusion : The patients with the mean trough concentration of the vancomycin higher than 15 mg/L had significantly higher rates of the two consecutive growth-negative blood cultures, and there was no significant difference in the incidence of renal toxicity. Thus, increasing the vancomycin trough concentration to 15 mg/L or higher could enhance the therapeutic effect without significant increase in the nephrotoxicity.
참고문헌 (27)
- Michael Rybak, "Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists", Am J Health Syst Pharm, 66(1), pp.82~98 (2009)
- Sasima Tongsai, "The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis", BMC Res Notes, 9(1), pp.455~ (2016)
- 추은주, "메티실린 내성 황색포도알균 감염의 항생제 치료", 대한의사협회지, 61(3), pp.207~213 (2018), 대한의사협회[DOI]
- Catherine Liu, "Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children", Clin Infect Dis, 52(3), pp.18~55 (2011)
- Cheol-in kang, "What’s new in the management of bacterial infections in the era of multidrug-resistant bacteria", The Journal of the Korean Society for Transplantation, 27(3), pp.81~86 (2013)
- 손기호, "MRSA 폐렴 환자에서 Vancomycin trough 농도 및 AUC24", MIC의 항 미생물학적 효과 비교, 2013, pp.30(3), 202~209[DOI]
- Marisel Segarra-Newnham, "Pharmacotherapy for Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia", Ann Pharmacotherapy, 46(12), pp.1678~1687 (2012)
- J E Geraci, "Vancomycin", Mayo Clin Proc, 52(10), pp.631~634 (1977)
- Benjamin P Howden, "Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility", Clin Infect Dis, 38(4), pp.521~528 (2004)
- Thomas P Lodise, "Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients", Clin Infect Dis, 49(4), pp.507~514 (2009)
- John A Bosso, "Relationship between vancomycin trough concentrations and nephrotoxicity : a prospective multicenter trial", Antimicrob Agents Chemother, 55(12), pp.5475~5479 (2011)
- 송수정, "Vancomycin의 TDM을 의뢰한 환자에서 신기능 변화에 대한 위험인자 분석", 병원약사회지, 29(3), pp.313~323 (2012), 한국병원약사회[DOI]
- 송준영, "다제내성 그람양성균 감염증의항생제 치료", J. Kor. Medicine, 71(2), pp.786~803 (2006)
- C Kaech, "Course and outcome of Staphylococcus aureus bacteraemia : a retrospective analysis of 308 episodes in a Swiss tertiary-care centre", Clin Microbiol Infect, 12(4), pp.345~352 (2006)
- D E Craven, "Vancomycin Treatment of Bacteremia Caused by Oxacillin-Resistant Staphylococcus Aureus : Comparison with Beta-Lactam Antibiotic Treatment of Bacteremia Caused by Oxacillin-Sensitive Staphylococcus Aureus", J Infect Dis, 147(1), pp.137~143 (1983)
- 이혁민, "2004년도 국내 12개 병원에서 분리된 주요 세균의 항균제 내성율", Annals of Clinical Microbiology, 8(1), pp.66~73 (2005), 대한임상미생물학회
- T P Lodise, "Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin", Antimicrob Agents Chemother, 52(9), pp.3315~3320 (2008)
- Sheryl Zelenitsky, "Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock", Int J Antimicrob Agents, 41(3), pp.255~260 (2013)
- Ravina Kullar, "Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort", Pharmacotherapy, 32(3), pp.195~201 (2012)
- Elizabeth D Hermsen, "Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deepseated infections", 9(1), pp.9~14 (2010)
- Lindsey Pritchard, "Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity", Am J Med, 123(12), pp.1143~1149 (2010)
- 임나리, "Vancomycin에 의한 신독성 발생에 영향을 미치는 위험인자 분석", 병원약사회지, 32(1), pp.44~53 (2015), 한국병원약사회[DOI]
- B F Farber, "Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981", Antibicrob Agents Chemother, 23(1), pp.138~141 (1983)
- Meghan N. Jeffres, "A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin resistant Staphylococcus aureus pneumonia", Clinical therapeutics, 29(6), pp.1107~1115 (2007)
- Thomas P Lodise, "Larger vancomycin doses(at least four grams per day)are associated with an increased incidence of nephrotoxicity", Antimicob Agents Chemother, 52(4), pp.1330~1336 (2008)
- J E Geraci, "Antibiotic therapy of bacterial endocarditis:VII. Vancomycin for acute micrococcal endocarditis", Proc staff Meet Mayo Clin, 33(7), pp.172~181 (1958)
- P E Hermans, "Vancomycin", Mayo Clin Proc, 62(10), pp.901~905 (1987)